Is Parse Biosciences still an independent company in 2026?

No. Parse Biosciences was acquired by QIAGEN in a deal announced November 4, 2025 for about $225 million upfront plus up to $55 million in milestones, and the transaction closed in December 2025, making Parse a wholly owned QIAGEN subsidiary.

Who owns Parse Biosciences now?

QIAGEN N.V. (NYSE: QGEN) owns Parse Biosciences after completing its acquisition in December 2025. Notably, QIAGEN itself is now reportedly a takeover target, with EQT, Advent, and KKR circling it at $50 plus per share as of July 2026.

Is joining Parse Biosciences a safe career move right now?

It is uncertain. Parse had about 110 employees at its November 2025 acquisition and no layoffs have been reported, but QIAGEN, its new parent, is itself under active takeover speculation as of July 2026 and its CEO is stepping down, adding stacked ownership risk.

Could AI replace what Parse Biosciences does?

Not directly. Parse's core value is patented wet-chemistry, split-pool barcoding with 30+ patents licensed from University of Washington and instrument-free lab workflows locking in 3,000+ customer labs as of November 4, 2025, which AI cannot substitute; only downstream data-analysis software faces AI competition.

Who is Parse Biosciences' biggest competitor?

10x Genomics is the dominant incumbent in single-cell sequencing and acquired direct Parse rival Scale Biosciences in summer 2025. 10x Genomics and Stanford University are also in active patent litigation against Parse (case 1:22-cv-01117, Delaware), with claim-construction rulings through February 2025.

How much revenue does Parse Biosciences generate?

Parse does not disclose standalone financials, but QIAGEN guided that Parse is expected to contribute approximately $40 million in sales for full year 2026, about two percentage points of QIAGEN's growth, with strong double-digit growth projected in subsequent years, per QIAGEN's November 4, 2025 announcement.

Biotech tools companies · subsidiary of QIAGEN N.V. (NYSE: QGEN) · United States

Parse Biosciences, Inc.

parsebiosciences.com ↗

Maker of split-pool barcoding kits for single-cell sequencing, now owned by QIAGEN.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: Ruling expected in 10x Genomics/Stanford v. Parse patent case (Delaware 1:22-cv-01117)

The call

Parse's lab chemistry and customer base look solid, but its fate now rides on QIAGEN's ownership churn and a live patent fight with 10x Genomics.

Parse Biosciences sells instruments and chemicals that let researchers tag and study individual cells without needing expensive machines. The company has strong patents and thousands of loyal customers, which would normally make it hard to replace, but its real problem is not science: QIAGEN bought Parse in late 2025, and now private equity firms are trying to buy QIAGEN itself, creating uncertainty about whether Parse stays independent or gets merged with 10x Genomics (a rival that already bought another competitor called Scale). The one thing that could stabilize Parse is if QIAGEN's leadership stays in place and the patent fight with 10x stays in Parse's favor, but both are in doubt right now.

Why

AI pressure: None apparent. AI tools analyze the data Parse's kits generate; they don't replace the wet-lab chemistry itself. Could AI do the core job? Unlikely.

Bigger players: 10x Genomics. 10x Genomics bought rival Scale Biosciences in 2025 and is suing Parse over single-cell patents in Delaware federal court. Could a giant copy it? Yes, easily.

What protects it. 30+ split-pool barcoding patents from University of Washington and 3,000+ labs already running Parse kits day to day.

What would change this call

Delaware court rules on 10x Genomics/Stanford v. Parse patent case (1:22-cv-01117). Loss or bad licensing terms would weaken Parse's IP moat and pricing power.
QIAGEN announces EQT, Advent, or KKR takeover or names new CEO within 12 months. Ownership churn could deprioritize or restructure Parse's business unit.
QIAGEN reports Parse's actual 2026 revenue against the ~$40M guidance. A miss would signal integration trouble or customer attrition post-acquisition.

Key numbers

QIAGEN paid about $225M upfront, up to $280M total (2025-11-04)
Parse guided to ~$40M revenue for QIAGEN in FY2026 (2025-11-04)
3,000+ lab customers across 40+ countries (2025-11-04)

Named risks

QIAGEN change of control via EQT, Advent, or KKR takeover could restructure or deprioritize Parse. Severity: high
Ongoing 10x Genomics/Stanford patent litigation could restrict Parse's freedom to operate. Severity: high
QIAGEN CEO succession still pending as of July 2026 creates leadership uncertainty during integration. Severity: medium
Parse revenue must hit ~$40M 2026 guidance to justify acquisition thesis; shortfall could trigger integration cuts. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
10x Genomics	contesting	Active patent suit with Stanford against Parse in Delaware, rulings through Feb 2025; acquired rival Scale Biosciences in summer 2025
Scale Biosciences (owned by 10x Genomics)	gaining on	Parse won partial invalidity challenge against Scale/Roche patent in October 2025
Illumina	contesting	Acquired Fluent BioSciences to gain single-cell sample-prep capability, part of 2025-2026 consolidation wave
QIAGEN (now parent)	losing to	Parse acquired outright by QIAGEN for ~$225M, closed December 2025, ending independent status

Questions people ask

Is Parse Biosciences still an independent company in 2026?: No. Parse Biosciences was acquired by QIAGEN in a deal announced November 4, 2025 for about $225 million upfront plus up to $55 million in milestones, and the transaction closed in December 2025, making Parse a wholly owned QIAGEN subsidiary.
Who owns Parse Biosciences now?: QIAGEN N.V. (NYSE: QGEN) owns Parse Biosciences after completing its acquisition in December 2025. Notably, QIAGEN itself is now reportedly a takeover target, with EQT, Advent, and KKR circling it at $50 plus per share as of July 2026.
Is joining Parse Biosciences a safe career move right now?: It is uncertain. Parse had about 110 employees at its November 2025 acquisition and no layoffs have been reported, but QIAGEN, its new parent, is itself under active takeover speculation as of July 2026 and its CEO is stepping down, adding stacked ownership risk.
Could AI replace what Parse Biosciences does?: Not directly. Parse's core value is patented wet-chemistry, split-pool barcoding with 30+ patents licensed from University of Washington and instrument-free lab workflows locking in 3,000+ customer labs as of November 4, 2025, which AI cannot substitute; only downstream data-analysis software faces AI competition.
Who is Parse Biosciences' biggest competitor?: 10x Genomics is the dominant incumbent in single-cell sequencing and acquired direct Parse rival Scale Biosciences in summer 2025. 10x Genomics and Stanford University are also in active patent litigation against Parse (case 1:22-cv-01117, Delaware), with claim-construction rulings through February 2025.
How much revenue does Parse Biosciences generate?: Parse does not disclose standalone financials, but QIAGEN guided that Parse is expected to contribute approximately $40 million in sales for full year 2026, about two percentage points of QIAGEN's growth, with strong double-digit growth projected in subsequent years, per QIAGEN's November 4, 2025 announcement.

Timeline

2026-07-10EQT, Advent, KKR reported circling QIAGEN with offers at $50 plus per share
2026-04-06Industry analysis notes five plus tools companies rolled up single-cell startups in 2025 to 2026
2026-02-04Reports confirm Parse acquisition by QIAGEN closed in December 2025
2026-01-21Bloomberg reports QIAGEN exploring possible sale after new buyer talks
2025-12-01QIAGEN completes acquisition of Parse Biosciences
2025-11-04QIAGEN announces definitive agreement to acquire Parse for about $225M plus $55M milestones
2025-11-04QIAGEN CEO Thierry Bernard announces he will step down once successor named
2025-10-09Court invalidates Scale Biosciences/Roche patent asserted against Parse
2025-02-19Parse launches Evercode WT Penta kit, 5 million cells and 384 samples per run
2024-10-29Parse launches GigaLab, scaling to 2.5 billion cells per year capacity

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation